Switch to Patients and Caregivers
Email Page
Print PagePatient Assistance Programs from Tarceva Access Solutions
We recognize the financial burdens that some patients and their families may experience in gaining access to our medicines. We are committed to assisting all eligible patients obtain access to our medicines, regardless of their ability to pay.
Through Tarceva Access Solutions, you can access several different patient assistance programs, depending on your patient’s situation.
- Your patient is uninsured or rendered uninsured by payer denial
- Your patient has health insurance and needs help with their co-pay*
- Your patient has private health insurance and you want to learn more about the Tarceva co-pay card
TARCEVA (erlotinib) INDICATIONS AND USAGE
Non-Small Cell Lung Cancer
Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
Results from two multicenter, placebo controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy, and its use is not recommended in that setting.
Pancreatic Cancer
Tarceva in combination with gemcitabine is indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Tarceva Important Safety Information
- There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic cancer or other advanced solid tumors.
- Cases of hepatic failure, hepatorenal syndrome, acute renal failure (all including fatalities), and renal insufficiency have been reported during use of Tarceva.
- Gastrointestinal perforation (including fatalities) has been reported in patients receiving Tarceva.
- Bullous, blistering and exfoliative skin conditions have been reported including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, which in some cases were fatal.
- In the pancreatic cancer trial, other serious adverse reactions associated with Tarceva plus gemcitabine and which may have included fatalities, were myocardial infarction/ischemia, cerebrovascular accident and microangiopathic hemolytic anemia with thrombocytopenia.
- Corneal perforation and ulceration have been reported during use of Tarceva.
- When receiving Tarceva therapy, women should be advised against becoming pregnant or breastfeeding. Tarceva is pregnancy category D.
- The most common adverse reactions in patients with NSCLC receiving Tarceva monotherapy 150 mg were rash and diarrhea.
- The most common adverse reactions in patients with pancreatic cancer receiving Tarceva 100 mg plus gemcitabine were fatigue, rash, nausea, anorexia and diarrhea.
For additional information, please see accompanying full prescribing information.
*Co-pay refers to a cost-sharing arrangement in which members of health insurance plans pay a specified charge for a product or service, such as a prescription or an office visit. Members are typically responsible for this payment at the time of service.
